BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PregLem SA Announces In-Licensing Deal With Merck Serono For Post-Operative Adhesions & Endometriosis


8/11/2010 8:26:29 AM

Geneva, Switzerland, 11 August 2010: PregLem, the Swiss specialty biopharmaceutical company focused on women’s reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

Approximately four million pelvic and abdominal surgery procedures are performed each year in the US and a similar number is estimated for EU.1 Adhesion formation is a common outcome of these surgeries, occurring in 90-95% of patients2. There can be an adhesion between organs in the pelvis, bowel to bowel, bowel to uterus, bowel to the ovary, or to the abdominal wall. At their most extreme they can result in infertility, pain and bowel obstructions. Approximately 10-15% of patients will have clinically significant problems that in some cases may require readmission to hospital for treatment or reoperation as a result.

In addition, endometriosis itself as well as its surgery are leading causes of pelvic adhesions in pre-menopausal women. Endometriosis, a condition characterised by disturbing pelvic pain and infertility, affects over 16 million women in the world.

There are no pharmacological products available to assist in the prevention of post surgical adhesions. Surgeons currently use medical devices (commonly films, sprays or solutions) which have been shown to be marginally effective and often impractical. The prevention of post surgical adhesion thus presents a major unmet medical need.

JNK-I (PGL5) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative adhesions. Preclinical data show that the compound is an effective anti-inflammatory with anti-fibrotic properties.

PregLem plans to initiate a clinical proof of concept study and a phase II study during 2011 for the prevention of post-surgical abdominal adhesions and/or endometriosis in patients with tubal ligation or comparable effective contraception.

Ernest Loumaye, CEO & Co-Founder of PregLem, said:

“Bentamapimod is an innovative compound with the potential of a unique combination of anti-adhesions and anti-endometriosis properties, therefore presenting a significant opportunity in addressing this global market need. It is also a perfect strategic fit with our specialty product portfolio focused on women’s reproductive medicine. This agreement further validates our business model of in-licensing promising clinical stage assets for late stage development.”

1 U.S. UK, Germany, France, Spain, Italy Surgical Procedure Volumes, Medtech Insight, March 2009 2 Postoperative abdominal adhesions and their prevention in gynecological surgery. Expert Consensus, Gynecol Surg 2007 (4):243-253 PregLem recently announced positive Phase III data on its lead drug candidate – Esmya™ – for the effective treatment of uterine fibroids (myoma). The results enable PregLem to submit a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) which is expected to take place during the 4th quarter of 2010. Upon approval, PregLem expects to launch the product in major European markets.

For further information, please contact:

PregLem: Désirée Andrey CEO Office PregLem SA Tel: +41 (0)22 884 03 40 desiree.andrey@preglem.com

Capital MS&L: Mary Clark, Anna Davies Tel: +44 (0)20 7307 5330 preglem@capitalmsl.com

About PregLem

PregLem is a Swiss speciality biopharmaceutical company, dedicated to the development and commercialization of a new class of drugs for women’s reproductive health conditions. PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products. The company is backed by a blue chip investor base.

Visit www.preglem.com for more information.

About post-operative adhesions & endometriosis

Four million people each year have pelvic and abdominal surgeries in the US. Post-operative adhesions are a natural consequence of tissue trauma and healing and they occur in 90- 95% of patients. At their most extreme can result in infertility, pain and bowel obstructions. 10-15% of patients will have clinically significant problems that in some cases may require readmission to hospital for treatment or reoperation as a result.

There is currently no pharmacological treatment available to prevent post-operative adhesions. Instead surgical techniques and medical devices are currently used as a preventative measure. However, data shows that this is frequently ineffective.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->